TESARO Inc (TSRO) Given Average Recommendation of “Buy” by Brokerages

TESARO Inc (NASDAQ:TSRO) has been assigned a consensus recommendation of “Buy” from the twenty-one research firms that are presently covering the firm. Eight investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $169.71.

Several research analysts have commented on TSRO shares. Leerink Swann reissued an “outperform” rating and issued a $152.00 price objective (up from $115.00) on shares of TESARO in a research report on Monday, January 9th. Morgan Stanley started coverage on TESARO in a research note on Friday, January 13th. They set an “overweight” rating and a $172.00 target price for the company. Credit Suisse Group AG set a $151.00 target price on TESARO and gave the company a “buy” rating in a research note on Thursday, January 12th. FBR & Co reiterated a “buy” rating on shares of TESARO in a research note on Thursday, January 12th. Finally, Wedbush reiterated an “outperform” rating and issued a $166.00 price target (up from $139.00) on shares of TESARO in a research note on Saturday, January 14th.

In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of TESARO stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $153.02, for a total transaction of $126,853.58. Following the transaction, the senior vice president now directly owns 6,522 shares in the company, valued at approximately $997,996.44. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Grant C. Bogle sold 1,447 shares of TESARO stock in a transaction that occurred on Thursday, March 2nd. The stock was sold at an average price of $177.61, for a total transaction of $257,001.67. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,432 shares of company stock worth $2,902,602. 40.50% of the stock is owned by corporate insiders.

Institutional investors have recently bought and sold shares of the company. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in TESARO during the first quarter valued at $415,000. Swiss National Bank boosted its position in TESARO by 4.2% in the first quarter. Swiss National Bank now owns 61,578 shares of the biopharmaceutical company’s stock valued at $9,475,000 after buying an additional 2,500 shares during the last quarter. Smith Asset Management Group LP boosted its position in TESARO by 16.8% in the first quarter. Smith Asset Management Group LP now owns 6,940 shares of the biopharmaceutical company’s stock valued at $1,068,000 after buying an additional 1,000 shares in the last quarter. Pictet Asset Management Ltd. boosted its position in TESARO by 8.1% in the first quarter. Pictet Asset Management Ltd. now owns 286,236 shares of the biopharmaceutical company’s stock valued at $44,043,000 after buying an additional 21,337 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in TESARO by 35.0% in the first quarter. Bank of New York Mellon Corp now owns 675,597 shares of the biopharmaceutical company’s stock valued at $103,954,000 after buying an additional 175,273 shares in the last quarter. Hedge funds and other institutional investors own 98.48% of the company’s stock.

TESARO (NASDAQ:TSRO) opened at 143.59 on Friday. The stock’s 50 day moving average price is $147.11 and its 200-day moving average price is $146.86. TESARO has a 52-week low of $36.68 and a 52-week high of $192.94. The company’s market cap is $7.70 billion.

ILLEGAL ACTIVITY WARNING: “TESARO Inc (TSRO) Given Average Recommendation of “Buy” by Brokerages” was originally published by BBNS and is owned by of BBNS. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://baseballnewssource.com/markets/tesaro-inc-tsro-receives-174-16-average-price-target-from-analysts-updated-updated/580621.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO

Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with our FREE daily email newsletter.

 


Latest News

MLB and Facebook Announce Live Streaming for Games
MLB and Facebook Announce Live Streaming for Games
Can Anyway Stop the Houston Astros?
Can Anyway Stop the Houston Astros?
Kevin Pillar Turns from Defense to Offense
Kevin Pillar Turns from Defense to Offense
Chris Iannetta Hit in Face with 93mph Fastball
Chris Iannetta Hit in Face with 93mph Fastball
Ryan Zimmerman Resurgence Once Again Helping Nationals
Ryan Zimmerman Resurgence Once Again Helping Nationals
Cody Bellinger Knocking the Cover Off the Ball
Cody Bellinger Knocking the Cover Off the Ball


Leave a Reply

 
© 2006-2017 BBNS.